CBD (Cannabidiol) for Alzheimer's Disease Agitation - NCT06014424

Overview

flowchart TD
    clinical_trials_nct06014424_cb["CBD Cannabidiol for Alzheimers Disease Agitat"]
    style clinical_trials_nct06014424_cb fill:#4fc3f7,stroke:#333,color:#000
    clinical_trials_nct0_0["Trial Details"]
    clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_0
    style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000
    clinical_trials_nct0_1["Background: Agitation in Alzheimers Disease"]
    clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_1
    style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000
    clinical_trials_nct0_2["Definition and Prevalence"]
    clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_2
    style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000
    clinical_trials_nct0_3["Impact on Caregiving"]
    clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_3
    style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000
    clinical_trials_nct0_4["Current Treatment Landscape"]
    clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_4
    style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000
    clinical_trials_nct0_5["Study Description"]
    clinical_trials_nct06014424_cb -->|"includes"| clinical_trials_nct0_5
    style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000

NCT06014424 is a Phase 2 clinical trial investigating the efficacy of cannabidiol (CBD) for managing agitation in Alzheimer’s disease patients. The study is conducted at Sunnybrook Health Sciences Centre in Toronto, Canada, representing a significant investigation into non-psychotropic cannabinoid therapy for behavioral symptoms in neurodegenerative disease

Agitation represents one of the most challenging aspects of Alzheimer’s disease care, affecting approximately 50-80% of patients at some point during disease progression. This symptom significantly impacts quality of life for both patients and caregivers, often leading to institutionalization and increased healthcare costs.

Trial Details

Background: Agitation in Alzheimer’s Disease

Definition and Prevalence

Agitation in dementia encompasses a spectrum of behaviors including restlessness, pacing, verbal aggression, physical aggression, and disinhibition. According to the Cohen-Mansfield Agitation Inventory (CMAI), these behaviors are categorized into physically non-aggressive behaviors (pacing, inappropriate robing), verbally aggressive behaviors (screaming, complaining), and physically aggressive behaviors (hitting, kicking)^{1Behavioral and psychological symptoms of dementia2019 · Nat Rev Dis Primers · PMID 31229142Open reference}.

The prevalence of agitation increases with disease severity:

• Mild AD: 30-40% experience agitation

• Moderate AD: 50-60% experience agitation

• Severe AD: 70-80% experience agitation

Impact on Caregiving

Agitation is a leading cause of caregiver burnout and institutionalization:

1. Caregiver stress: Constant vigilance and management of agitation leads to physical and emotional exhaustion

2. Safety concerns: Aggressive behaviors pose risks to both patient and caregiver

3. Economic burden: Behavioral symptoms account for up to 40% of dementia care costs

4. Quality of life: Agitation significantly diminishes quality of life for patients and families

Current Treatment Landscape

Non-pharmacological approaches are first-line treatment:

• Environmental modifications

• Music therapy

• Pet therapy

• Structured activities

• Caregiver education

Pharmacological options are limited and often suboptimal:

• Antipsychotics: Black box warning for increased mortality

• Benzodiazepines: Risk of sedation, falls, cognitive worsening

• Antidepressants: Variable efficacy, side effects

• Acetylcholinesterase inhibitors: Modest benefit for some patients

This underscores the urgent need for novel therapeutic approaches with better safety profiles.

Study Description

Rationale for CBD

Cannabidiol (CBD) has emerged as a promising candidate for managing behavioral symptoms in dementia for several reasons^{2Molecular targets of the phytocannabinoids2017 · Prog Neuropsychopharmacol Biol Psychiatry · PMID 28089419Open reference}:

Non-psychotropic properties: Unlike tetrahydrocannabinol (THC), CBD does not produce psychoactive effects, making it suitable for elderly patients with cognitive impairment.

Multiple mechanisms of action: CBD interacts with numerous receptor systems implicated in agitation:

• Endocannabinoid system modulation (CB1, CB2 receptors)

• Serotonin 5-HT1A receptor agonism

• PPAR-gamma nuclear receptor activation

• TRPV1 vanilloid receptor modulation

• Anti-inflammatory effects via COX-2 inhibition

Safety profile: CBD has been shown to have a favorable safety profile in clinical trials, with mild to moderate side effects including dry mouth, drowsiness, and diarrhea.

Preclinical Evidence

Several preclinical studies support CBD’s potential for neurodegenerative applications^{3Cannabidiol for neurodegenerative disorders2012 · Br J Clin Pharmacol · PMID 22689829Open reference}:

• Neuroprotection: CBD protects against amyloid-beta induced neurotoxicity in vitro

• Anti-inflammatory: Reduces microglial activation and pro-inflammatory cytokines

• Antioxidant: Scavenges free radicals and reduces oxidative stress

• Anti-apoptotic: Prevents neuronal cell death in cellular models

Clinical Evidence

While direct clinical trial data for CBD in Alzheimer’s agitation is limited, related evidence exists^{4THC and CBD in dementia2021 · J Alzheimers Dis · PMID 33504177Open reference}:

• Dementia-related behaviors: Small studies show THC/CBD combinations may reduce agitation

• Parkinson’s disease: CBD has been studied for psychosis and motor symptoms

• Epilepsy: CBD safety established in thousands of pediatric and adult patients

• Anxiety: CBD demonstrates anxiolytic effects in clinical trials

Proposed Mechanism in Agitation

CBD may address agitation through multiple pathways^{5Cannabis derivatives for Alzheimer's2022 · Psychopharmacology · PMID 35004983Open reference}:

1. Anxiolytic effects: 5-HT1A receptor agonism reduces anxiety, a common trigger for agitation

2. Sleep regulation: CBD may improve sleep-wake cycles disrupted in dementia

3. Anti-inflammatory: Neuroinflammation contributes to behavioral symptoms

4. Neuroprotection: May slow underlying neurodegeneration affecting behavior regulation

Study Design

Cross-over Methodology

The cross-over design offers several advantages for this trial:

Within-patient comparison: Each patient serves as their own control, eliminating inter-individual variability.

Efficient sample size: Fewer participants needed compared to parallel-group designs.

Treatment sequence: Patients receive both CBD and placebo in randomized order, with washout periods between treatments.

Blinding: Both patients and investigators are blinded to treatment allocation until trial completion.

Treatment Protocol

Dosage Considerations

CBD dosing in clinical trials varies widely:

• Low dose: 10-20 mg/day

• Medium dose: 50-100 mg/day

• High dose: 200-500 mg/day

The optimal dose for agitation will be determined through dose-escalation components of the trial.

Outcome Measures

Primary Endpoints

Secondary Endpoints

• Sleep quality (actigraphy, sleep diaries)

• Caregiver burden (Zarit Burden Interview)

• Cognitive function (MMSE, ADAS-Cog)

• Safety and tolerability

• Quality of life (QoL-AD)

Exploratory Endpoints

• Biomarker collection (inflammatory markers)

• Pharmacokinetic sampling

• Adverse event monitoring

Inclusion Criteria

Key inclusion criteria:

1. Clinical diagnosis of Alzheimer’s disease

2. Clinically significant agitation (CMAI score >= 25)

3. Age 60-90 years

4. Stable AD medications (if any) for >=4 weeks

5. Available caregiver/informant

6. Able to swallow capsules

Exclusion Criteria

Key exclusion criteria:

1. Prior cannabis use disorder

2. Significant liver dysfunction (elevated LFTs >3x ULN)

3. Current use of CBD or cannabis products

4. Severe medical conditions

5. Psychotic disorders unrelated to dementia

6. Contraindications to study procedures

Safety Considerations

CBD Safety Profile

CBD is generally well-tolerated with a favorable safety profile:

Drug Interactions

CBD may interact with certain medications through CYP450 enzyme inhibition:

• Warfarin: May increase INR

• Anticonvulsants: May alter levels

• Antidepressants: May increase levels of some SSRIs

• Antipsychotics: May increase levels of some agents

Special Populations

Elderly patients require careful monitoring:

• Start low, go slow dosing strategy

• Renal and hepatic function monitoring

• Orthostatic hypotension precautions

• Fall risk assessment

Clinical Implications

Potential Benefits

If successful, this trial could provide:

1. Novel treatment option: First evidence-based CBD formulation for AD agitation

2. Improved safety: Better side effect profile than antipsychotics

3. Natural product appeal: Patient/caregiver preference for plant-based options

4. Disease-modifying potential: Neuroprotective effects may slow progression

Challenges

Several challenges remain:

• Variable response: Individual variability in CBD metabolism

• Dosing optimization: Finding optimal dose for geriatric population

• Long-term effects: Unknown effects with extended use

• Regulatory status: CBD remains controlled substance in some jurisdictions

Regulatory Considerations

FDA Status

CBD products occupy a complex regulatory space:

• Epidiolex (CBD for epilepsy) is FDA-approved

• CBD in dietary supplements remains legally uncertain

• CBD for neurological indications requires prescription

Health Canada Context

As the trial is conducted in Canada, Health Canada regulations apply:

• CBD is legal for medical purposes with prescription

• Product quality and consistency are regulated

• Clinical trial authorization required

Endocannabinoid System in Alzheimer’s Disease

The Endocannabinoid System

The endocannabinoid system (ECS) is a complex signaling network involved in numerous physiological processes

Components:

• Endogenous cannabinoids (anandamide, 2-AG)

• Cannabinoid receptors (CB1, CB2)

• Metabolic enzymes (FAAH, MAGL)

Distribution:

• CB1: abundant in brain (hippocampus, cortex, basal ganglia)

• CB2: primarily immune cells, low in healthy brain

• Both upregulated in neurodegeneration

ECS Dysfunction in AD

The ECS is altered in Alzheimer’s disease:

CB1 Receptor Changes:

• Reduced CB1 density in AD brains

• Correlates with cognitive decline

• Linked to neurotransmitter dysfunction

CB2 Receptor Upregulation:

• Increased CB2 in activated microglia

• Marker of neuroinflammation

• Potential therapeutic target

Endocannabinoid Levels:

• Elevated anandamide in AD CSF

• Correlates with disease severity

• Suggests compensatory mechanism

CBD Mechanisms in AD

CBD exerts multiple effects relevant to AD

Anti-inflammatory Effects:

• Reduces microglial activation

• Decreases pro-inflammatory cytokines

• Modulates neuroinflammation

Neuroprotection:

• Protects against amyloid toxicity

• Reduces tau phosphorylation

• Supports mitochondrial function

Synaptic Function

• Enhances synaptic plasticity

• Improves memory in models

• Modulates neurotransmitter release

Clinical Trial Design Considerations

Cross-over Trial Strengths

Statistical Efficiency:

• Each patient serves as their own control

• Reduces inter-subject variability

• Requires smaller sample size

Practical Advantages:

• All patients receive active treatment

• Patient preference considerations

• Ethical appeal of no placebo-only group

Limitations:

• Carryover effects between periods

• Cannot separate treatment from time effects

• May not be suitable for progressive diseases

Agitation Assessment Tools

Cohen-Mansfield Agitation Inventory (CMAI):

• 29-item behavioral checklist

• Frequency ratings (1-7 scale)

• Categories: physical/verbal aggressive, non-aggressive

Neuropsychiatric Inventory (NPI):

• 12 behavioral domains

• Frequency and severity scoring

• Caregiver distress ratings

Agitation Efficacy Scale:

• Newly validated for clinical trials

• Combines multiple assessment modalities

Safety and Pharmacology

CBD Pharmacokinetics

Absorption:

• Oral bioavailability: 6-19%

• Affected by food intake

• Tmax: 2-3 hours

Distribution:

• Highly protein bound

• Wide tissue distribution

• Crosses blood-brain barrier

Metabolism:

• hepatic CYP2C19, CYP3A4

• Extensive first-pass metabolism

• Active metabolites

Elimination:

• Half-life: 18-32 hours

• Fecal excretion predominant

• Terminal elimination complex

Geriatric Considerations

Elderly patients require special attention

Pharmacokinetic Changes:

• Reduced hepatic metabolism

• Decreased renal clearance

• Altered protein binding

Pharmacodynamic Sensitivity:

• Increased CNS sensitivity

• Fall risk considerations

• Cognitive effects monitoring

Dosing Strategy:

• Start low (10-20 mg/day)

• Slow titration

• Individualized approach

Drug-Drug Interactions

CBD inhibits cytochrome P450 enzymes:

Clinically Significant Interactions:

• Warfarin: Increased anticoagulation

• Anticonvulsants: Altered levels

• SSRI/SNRI: Serotonin syndrome risk

Monitoring Required:

• Valproate levels

• Clobazam levels

• Tacrolimus levels

Competitive Landscape

Other CBD Trials in Dementia

Multiple studies investigating cannabinoids in dementia:

Comparison of Cannabinoid Approaches

CBD Only:

• Non-psychotropic

• Wide dosing range

• Good safety profile

THC:CBD Combination:

• Entourage effect

• Psychoactive effects

• Limited in elderly

Synthetic Cannabinoids:

• Nabilone for agitation

• Dronabinol for appetite

• Limited evidence

Future Directions

Biomarker Development

Future trials may incorporate:

• Inflammatory biomarkers (IL-6, TNF-α)

• Neurofilament light chain

• Imaging correlates

Personalized Medicine

Potential for personalized approaches:

• Pharmacogenetic testing

• CB2 receptor genotyping

• Inflammation profiling

Related Pages

Related Conditions

• Alzheimer’s Disease

• Behavioral and Psychological Symptoms of Dementia

Related Therapeutics

• Cannabinoids in Neurodegeneration

• CBD for Neurodegeneration

• Non-pharmacological Dementia Treatments

Related Mechanisms

• Endocannabinoid System in Neurodegeneration

• Neuroinflammation Pathway

• Neurotransmitter Systems in Dementia

External Links

• ClinicalTrials.gov - NCT06014424

• Sunnybrook Health Sciences Centre

• Alzheimer’s Association Canada